Latest news with #RMTI
Yahoo
13-05-2025
- Business
- Yahoo
Rockwell Medical Inc (RMTI) Q1 2025 Earnings Call Highlights: Navigating Challenges and ...
Net Sales: $18.9 million, a 17% decrease from $22.7 million in Q1 2024. Gross Profit: $3 million, consistent with the same period in 2024. Gross Margin: 16%, up from 14% in Q1 2024. Net Loss: $1.5 million, improved from a net loss of $1.7 million in Q1 2024. Adjusted EBITDA: Negative $400,000. Cash, Cash Equivalents, and Investments: $17.3 million as of March 31, 2025, down from $21.6 million at December 31, 2024. Projected 2025 Net Sales Guidance: Between $65 million and $70 million. Projected 2025 Gross Margin Guidance: Between 16% and 18%. Projected 2025 Adjusted EBITDA Guidance: Between negative $500,000 and positive $500,000. Warning! GuruFocus has detected 3 Warning Signs with RMTI. Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Rockwell Medical Inc (NASDAQ:RMTI) successfully diversified its customer base by signing new contracts with leading regional, national, and global hemodialysis providers. The company maintained its gross margin within the guidance range for the year, demonstrating effective cost management. Rockwell Medical Inc (NASDAQ:RMTI) launched a new single-use bicarbonate cartridge technology, expanding its product portfolio and addressing a growing market segment. The company is actively pursuing business development opportunities that could strengthen its position in the renal market and provide access to new markets. Rockwell Medical Inc (NASDAQ:RMTI) reiterated its projected guidance for 2025, indicating confidence in achieving net sales between $65 million and $70 million. Net sales for the first quarter decreased by 17% compared to the same period in 2024, primarily due to the largest customer transitioning to another supplier. The company experienced a net loss of $1.5 million for Q1 2025, although this was an improvement over the previous year's loss. Adjusted EBITDA for Q1 2025 was negative $400,000, impacted by seasonal items associated with payroll tax and other expenses. Cash, cash equivalents, and investments decreased from $21.6 million at the end of 2024 to $17.3 million at the end of Q1 2025. The ongoing negotiations with the largest customer may result in a scaled-down contractual commitment, potentially impacting future revenue. Q: Can you provide an update on the negotiations with your largest historical customer and the potential scenarios that could arise from these discussions? Also, what is the expected revenue cadence for the remainder of 2025? A: Discussions with our largest customer are ongoing to maintain some level of service, likely at a smaller scale than before. We aim to establish a long-term arrangement to supply them, including replenishing their safety stock. Regarding revenue, we are in the process of acquiring new customers, which could be significant. We are confident in our guidance and expect Q2 to be the low point for the year, with improvements thereafter. Q: Could you comment on the at-home dialysis market and your specific product offerings in this area? A: The at-home dialysis market is progressing as expected and is growing. Our product offering for this market is gaining traction, and we anticipate increased sales in the second half of the year. This product not only improves patient experience but also offers higher margins for us. Q: Can you provide more information on your international market expansion, particularly on the West Coast? A: We are expanding primarily in Latin America, which presents significant opportunities. For the West Coast of the U.S., we see potential as it is largely supported by one manufacturer. We are considering establishing a facility there to capitalize on this opportunity, but no final decisions have been made yet. Q: How do you plan to mitigate the revenue loss from your largest customer transitioning to another supplier? A: We believe there are enough opportunities among small independent dialysis providers and within our existing footprint to replace a significant portion of the lost revenue. Our focus is on expanding our customer base domestically and internationally, particularly in Latin America. Q: Is the revenue guidance you reaffirmed today based on your current customer base, and could new customers provide potential upside? A: Yes, the guidance is based on our current customer base. Any new customers acquired during the year would provide potential upside to our revenue projections. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Washington Post
12-05-2025
- Business
- Washington Post
Rockwell Medical: Q1 Earnings Snapshot
WIXOM, Mich. — WIXOM, Mich. — Rockwell Medical Inc. (RMTI) on Monday reported a loss of $1.5 million in its first quarter. The Wixom, Michigan-based company said it had a loss of 4 cents per share. The maker of products used in the treatment of kidney disease and anemia posted revenue of $18.9 million in the period.
Yahoo
12-05-2025
- Business
- Yahoo
Rockwell Medical: Q1 Earnings Snapshot
WIXOM, Mich. (AP) — WIXOM, Mich. (AP) — Rockwell Medical Inc. (RMTI) on Monday reported a loss of $1.5 million in its first quarter. The Wixom, Michigan-based company said it had a loss of 4 cents per share. The maker of products used in the treatment of kidney disease and anemia posted revenue of $18.9 million in the period. Rockwell Medical expects full-year revenue in the range of $65 million to $70 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on RMTI at Sign in to access your portfolio
Associated Press
12-05-2025
- Business
- Associated Press
Rockwell Medical Announces First Quarter 2025 Results
WIXOM, Mich.--(BUSINESS WIRE)--May 12, 2025-- Rockwell Medical, Inc. (the 'Company') (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. 'During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis providers and health systems. We remain a preferred provider as a result of our continued reliability, high-quality products, and customer-centric approach,' said MarkStrobeck, Ph.D., Rockwell Medical's President and CEO. 'Additionally, we continued to consolidate and further automate our manufacturing operations to reduce expenses and sustain our gross margin despite our largest customer moving away from Rockwell Medical. We look forward to sharing more updates in the months ahead.' FIRST QUARTER 2025 FINANCIAL HIGHLIGHTS FIRST QUARTER 2025 OPERATING HIGHLIGHTS GUIDANCE Rockwell confirms its 2025 annual guidance as follows: CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: Speakers: Format: Discussion of first quarter 2025 financial and operational results followed by Q&A. NON-GAAP FINANCIAL MEASURES To supplement Rockwell Medical's unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America ('GAAP'), this press release also includes references to adjusted EBITDA, a non-GAAP financial measure that is defined as net income (loss) before net interest income (expense), net other income (expense), income tax expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual or not representative of underlying trends of our business, including but not limited to one-time severance costs, deferred revenue and inventory reserve amounts, if applicable for the periods presented. The Company has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to adjusted EBITDA. In addition, this press release includes a reference to adjusted EPS, a non-GAAP financial measure that is defined as adjusted EBITDA divided by the weighted average number of shares outstanding. The Company has also provided a reconciliation to EPS, or net income divided by the weighted average number of shares outstanding, which is the most directly comparable GAAP financial measure. Each of these adjusted measures is a non-GAAP financial measure. The Company has provided reconciliations to the GAAP measures at the end of this press release. Adjusted EBITDA and adjusted EPS are key measures used by Rockwell Medical to understand and evaluate operating performance and trends, to prepare and approve its annual budget, and to develop short- and long-term operating plans. The Company provides adjusted EBITDA because it believes the metric is helpful in highlighting trends in its operating results because it excludes items that are not indicative of Rockwell Medical's core operating performance. In particular, the Company believes that the exclusion of the items eliminated in calculating adjusted EBITDA provide useful measures for period-to-period comparisons of Rockwell Medical's business. This is also true for adjusted EPS, which is derived from adjusted EBITDA. Adjusted EBITDA and adjusted EPS should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of adjusted EBITDA and adjusted EPS as tools for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than the most directly comparable financial measures calculated in accordance with GAAP. When evaluating the Company's performance, you should consider adjusted EBITDA and adjusted EPS alongside other financial performance measures, including net loss, EPS and other GAAP results. ABOUT ROCKWELL MEDICAL Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work ® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & Production TM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions TM. For more information, visit FORWARD-LOOKING STATEMENTS Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as, 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'could,' 'can,' 'would,' 'develop,' 'plan,' 'potential,' 'predict,' 'forecast,' 'project,' 'intend,' 'look forward to,' 'remain confident,' 'feel confident,' 'guidance,' or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include (without limitation) statements regarding: expectations related to expenses for 2025 and annual guidance on net sales, gross margin and adjusted EBITDA. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include but are not limited to those risks more fully discussed in the 'Risk Factors' section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any subsequent reports filed with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law. Financial Tables Follow View source version on CONTACT: Heather R. Hunter SVP, Chief Corporate Affairs Officer (248) 432-1362 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MICHIGAN INDUSTRY KEYWORD: NURSING MEDICAL SUPPLIES MANUFACTURING DIABETES HEALTH PHARMACEUTICAL OTHER SCIENCE MEDICAL DEVICES OTHER MANUFACTURING HOSPITALS SCIENCE SOURCE: Rockwell Medical Copyright Business Wire 2025. PUB: 05/12/2025 06:00 AM/DISC: 05/12/2025 05:59 AM
Yahoo
21-03-2025
- Business
- Yahoo
Rockwell Medical Inc (RMTI) Q4 2024 Earnings Call Highlights: Strong Sales Growth Amidst ...
Net Sales (Full Year 2024): $101.5 million, a 21% increase over 2023. Net Sales (Q4 2024): $24.7 million, a 12% increase over Q4 2023. Gross Margin (Full Year 2024): 17%, up from 10% in 2023. Gross Margin (Q4 2024): 15%, up from 13% in Q4 2023. Gross Profit (Full Year 2024): $17.5 million, more than double from 2023. Gross Profit (Q4 2024): $3.6 million, a 27% increase over Q4 2023. Net Loss (Full Year 2024): $500,000, improved from a net loss of $8.4 million in 2023. Net Loss (Q4 2024): $800,000, a 50% improvement over Q4 2023. Adjusted EBITDA (Full Year 2024): $5.2 million, a $9 million improvement over 2023. Adjusted EBITDA (Q4 2024): $1.4 million, a 156% improvement over Q4 2023. Cash and Investments (End of 2024): $21.6 million, up from $10.9 million at the end of 2023. Projected Net Sales (2025): Between $65 million and $70 million. Projected Gross Margin (2025): Between 16% and 18%. Projected Adjusted EBITDA (2025): Between negative $500,000 to positive $500,000. Warning! GuruFocus has detected 4 Warning Signs with RMTI. Release Date: March 20, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Rockwell Medical Inc (NASDAQ:RMTI) achieved over $100 million in net sales for 2024, marking a significant milestone. The company improved its gross margin to 17% and achieved profitability on an adjusted EBITDA basis for the first time. Rockwell Medical Inc (NASDAQ:RMTI) successfully reduced fixed overhead costs by over $2 million annually through strategic contract terminations. The company expanded its product portfolio and customer base, including a significant distribution agreement with Nipro Medical Corporation. Rockwell Medical Inc (NASDAQ:RMTI) strengthened its cash position, increasing cash and investments to $21.6 million by the end of 2024. The largest customer of Rockwell Medical Inc (NASDAQ:RMTI) is transitioning to another supplier, resulting in an expected $34 million revenue loss in 2025. The company projects a decline in net sales for 2025, with guidance between $65 million and $70 million, down from 2024. Gross margin guidance for 2025 is slightly lower, between 16% and 18%, due to a reduced revenue base. The transition year of 2025 is expected to be challenging, with potential negative adjusted EBITDA. There is uncertainty regarding the outcome of ongoing discussions with the largest customer for future volume commitments. Q: Can you provide details on the revenue impact from your largest customer transitioning away and how it affects your 2025 guidance? A: (Mark Strobeck, CEO) The largest customer generated approximately $45 million in revenue, and we expect a $34 million decline in 2025 due to their transition. Our guidance does not include any potential future agreements with this customer, so any successful negotiations would be upside to our current projections. Q: Do you view 2025 as a transition year, and what are your expectations for growth in 2026? A: (Mark Strobeck, CEO) We see 2025 as a transition year but aim to return to growth within the year. We are actively pursuing new customers and business development opportunities to offset the revenue loss and drive future growth. Q: Are there any risks that other customers might also pivot away from Rockwell, and how do you plan to mitigate such risks? A: (Mark Strobeck, CEO) The decision by our largest customer was based on diversifying their supplier base, not due to any issues with our products or services. We maintain strong relationships and long-term contracts with other customers, and we are confident in our ability to continue serving them effectively. Q: How do you plan to grow the bicarbonate cartridge business in 2025, and what are your expectations for its uptake? A: (Timothy Chole, CCO) We plan to introduce the bicarbonate cartridge to our existing customer base, which should drive short-term sales. The market is gradually shifting towards machines compatible with these cartridges, providing long-term growth potential. Q: Can you elaborate on the factors affecting your gross margin guidance for 2025? A: (Jesse Neri, CFO) The gross margin guidance of 16% to 18% reflects the lower revenue base expected in 2025 compared to 2024. The removal of our largest customer, which contributed little to gross margin, should not significantly impact the overall percentage. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
